Orbital Therapeutics

United States - Cambridge, Massachusetts

• 27/04/2023
• Series A
• $270,000,000

Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines (excluding RNAi therapeutics) to treat human disease in ways that were not previously possible. We’re building a first-in-kind platform designed to sit at the intersection of RNA technology delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, protein replacement and regenerative medicine.

Founded by experts in the fields of genetic medicine and RNA development and delivery, we have a dynamic operational structure designed to harness the ingenuity of a deep and diverse team of scientists, drug developers and business leaders.

Related People

Giuseppe CiaramellaCo Founder

United States - Cambridge, Massachusetts

Senior pharmaceutical discovery leader with over 20 years of International drug discovery experience at Moderna, Astrazeneca, BI, Pfizer and Merck, covering roles from the early phases of drug discovery to the identification of small molecule and biological clinical candidates. Particular focus in the field of antivirals and biotherapeutics. Significant experience of conducting research through external partnerships and of building business plans for the assessment and in-licensing of pre-clinical and clinical assets, in collaboration with commercial/payer, clinical and financial functions.

LinkedIn https://www.linkedin.com/in/giuseppe-ciaramella-b417923/